Galmed and partner Barcode Nanotech have built a lipid-nanoparticle version of Aramchol designed to reach cardiac tissue. The science is early, and the company itself…
Small-cap pharma is where some of the market’s sharpest re-ratings happen, because a single clinical or regulatory milestone can change a company’s trajectory overnight. The…